Protagonist Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 21, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 21, 2025

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)


· · Year Ended December 31,
· 2024 · 2023 · 2022
Cash Flows from Operating Activities · · · ·
Net income (loss)	$275,188	$(78,955)	$(127,393)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation	37,554	29,293	24,202
Operating lease right-of-use asset amortization	2,069	2,335	2,335
Depreciation	826	977	1,034
Accretion of discount on marketable securities	(8,875)	(4,569)	(549)
Other	—	194	—
Changes in operating assets and liabilities:
Receivable from collaboration partner	(155,000)	(9,990)	1,556
Prepaid expenses and other assets	(3,768)	1,753	3,754
Research and development tax incentive receivable	—	—	2,686
Accounts payable	842	(2,868)	2,045
Payable to collaboration partner	(3)	(66)	(830)
Accrued expenses and other payables	4,289	(5,597)	(12,715)
Deferred revenue	30,567	—	(1,601)
Income taxes payable	2,689	—	—
Operating lease liability	(2,226)	(2,743)	(2,661)
Net cash provided by (used in) operating activities	184,152	(70,236)	(108,137)
Cash Flows from Investing Activities
Purchase of marketable securities	(621,702)	(191,045)	(214,874)
Proceeds from maturities of marketable securities	323,574	152,396	307,137
Purchases of property and equipment	(1,355)	(609)	(795)
Net cash (used in) provided by investing activities	(299,483)	(39,258)	91,468
Cash Flows from Financing Activities
Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan	26,453	4,774	4,448
Tax withholding payments related to net settlement of restricted stock units	(600)	(769)	(188)
Proceeds from public offering of common stock, net of issuance costs	—	107,798	—
Proceeds from at-the-market offering, net of issuance costs	—	24,302	14,553
Proceeds from exercise of Warrants in exchange for issuance of Pre-Funded Warrants	—	33,813	—
Proceeds from issuance of common stock upon exercise of Warrants	—	559	—
Issuance costs related to prior period common stock offering	—	—	25
Net cash provided by financing activities	25,853	170,477	18,838
Effect of exchange rate changes on cash, cash equivalents and restricted cash	—	—	(90)
Net (decrease) increase in cash, cash equivalents and restricted cash	(89,478)	60,983	2,079
Cash, cash equivalents and restricted cash, beginning of period	186,952	125,969	123,890
Cash, cash equivalents and restricted cash, end of period	$97,474	$186,952	$125,969
Supplemental Disclosure of Cash Flow Information:
Cash paid for taxes	$1,530	$—	$—
Supplemental Disclosure of Non-Cash Financing and Investing Information:
Right-of-use asset obtained in exchange for lease obligation	$10,511	$—	$—
Leasehold improvements obtained under tenant improvement allowance	$1,421	$—	$—
Purchases of property and equipment in accounts payable and accrued liabilities	$46	$61	$19

P****ROTAGONIST THERAPEUTICS, INC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.